Journal of Genetic Counseling

, Volume 22, Issue 2, pp 155–163 | Cite as

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer

  • Janice L. Berliner
  • Angela Musial Fay
  • Shelly A. Cummings
  • Brittany Burnett
  • Todd Tillmanns
Professional Development Paper

Purpose

The purpose of this document is to present a current and comprehensive set of practice recommendations for effective genetic cancer risk assessment, counseling and testing for hereditary breast and ovarian cancer. The intended audience is genetic counselors and other health professionals who care for individuals with, or at increased risk of, hereditary breast and/or ovarian cancer.

Keywords

Hereditary breast and ovarian cancer BRCA1 BRCA2 Cancer genetic counseling Risk assessment Medical management 

Supplementary material

10897_2012_9547_MOESM1_ESM.xls (36 kb)
ESM 1(XLS 35.5 KB)

References

  1. ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome (2009) Gynecologic Oncology, 113(1), 6–11.Google Scholar
  2. ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome (2009). Obstetrics and Gynecology, 113(4), 957–966.Google Scholar
  3. Alter, B. P., Rosenberg, P. S., & Brody, L. C. (2007). Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. Journal of Medical Genetics, 44(1), 1–9.PubMedCrossRefGoogle Scholar
  4. American College of Medical Genetics and Genomics. (2012). Policy statement: points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759–761.CrossRefGoogle Scholar
  5. American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397–2406.CrossRefGoogle Scholar
  6. American Society of Clinical Oncology. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28, 893–901.CrossRefGoogle Scholar
  7. Americans with Disabilities Act of 1990; www.ada.gov/pubs/ada.htm.
  8. Antoniou, A. C., Pharoah, P. D., McMullan, G., Day, N. E., Stratton, M. R., Peto, J., et al. (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. British Journal of Cancer, 86(1), 76–83.PubMedCrossRefGoogle Scholar
  9. Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in cases series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130.PubMedCrossRefGoogle Scholar
  10. Antoniou, A. C., Pharoah, P. D., Smith, P., & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580–1590.PubMedGoogle Scholar
  11. Armstrong, K., Eisen, A., & Weber, B. (2000). Assessing the risk of breast cancer. The New England Journal of Medicine, 342(8), 564–571.PubMedCrossRefGoogle Scholar
  12. Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology, 26, 4282–4288.PubMedCrossRefGoogle Scholar
  13. Begg, C. B., Haile, R. W., Borg, A., Malone, K. E., Concannon, P., et al. (2009). Variation of breast cancer risk among BRCA1/2 carriers. An investigation by the WECARE Study Group. JAMA, 299(2), 194–201.CrossRefGoogle Scholar
  14. Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P., et al. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 104, 7–10.PubMedCrossRefGoogle Scholar
  15. Bergman, A., Einbeigi, Z., Olofsson, U., Taib, Z., Wallgren, A., Karlsson, P., et al. (2001). The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. European Journal of Human Genetics, 9, 787–793.PubMedCrossRefGoogle Scholar
  16. Berliner, J. L., & Fay, A. M. (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 16(3), 241–260.PubMedCrossRefGoogle Scholar
  17. Berry, D. A., Parmigiani, G., Sanchez, J., Schildkraut, J., & Winer, E. (1997). Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute, 89(3), 227–238.PubMedCrossRefGoogle Scholar
  18. Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., et al. (2009). Breast cancer screening and diagnosis. JNCCN, 7, 1060–1096.PubMedGoogle Scholar
  19. Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., et al. (2006). Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology, 24(6), 863–871.PubMedCrossRefGoogle Scholar
  20. Claus, E., Risch, N., & Thompson, D. (1994). Autosomal dominant inheritance of early-onset breast cancer. Cancer, 73, 643–651.PubMedCrossRefGoogle Scholar
  21. Csokay, B., Udvarhelyi, N., Sulyok, Z., Besznyak, I., Ramus, S., Ponder, B., et al. (1999). High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Research, 59, 995–998.PubMedGoogle Scholar
  22. Edwards, S. M., Evans, D. G., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., et al. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918–924.PubMedCrossRefGoogle Scholar
  23. Fasouliotis, S. J., & Schenker, J. G. (2000). BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstetrical & Gynecological Survey, 55(6), 373–384.CrossRefGoogle Scholar
  24. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examine annually. Journal of the National Cancer Institute, 81, 1879–1886.PubMedCrossRefGoogle Scholar
  25. GeneTests (2012). http://www.genetests.org.
  26. Godard, B., Foulkes, W. D., Provencher, D., Brunet, J. S., Tonin, P. N., Mes-Masson, A. M., et al. (1998). Risk factors for familial and sporadic ovarian cancer among French Canadians: a case–control study. American Journal of Obstetrics and Gynecology, 179(2), 403–410.PubMedCrossRefGoogle Scholar
  27. Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., et al. (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clinical Cancer Research, 17(5), 1082–1089.PubMedCrossRefGoogle Scholar
  28. Greely, H. T. (2005). Banning genetic discrimination. NEJM, 353(9), 865–867.PubMedCrossRefGoogle Scholar
  29. Health Insurance Portability and Accountability Act of 1996, Pub L No 104–191; US Department of Health and Human Services: OCR Privacy Brief. Summary of the HIPAA Privacy Rule. http://www.hhs.gov/ocr/privacysummary.pdf.
  30. H.R. 493 (110th): Genetic Information Nondiscrimination Act of 2008, accessed at http://www.govtrack.us/congress/bills/110/hr493.
  31. Kauff, N. D., Mitra, N., Robson, M. E., Hurley, K. E., Chuai, S., Goldfrank, D., et al. (2005). Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. JNCI, 97(18), 1382–1384.PubMedCrossRefGoogle Scholar
  32. Lavie, O., Ben-Arie, A., Segev, Y., Faro, J., Barak, F., Haya, N., Auslender, R., & Gemer, O. (2010). BRCA germline mutations in women with uterine serous carcinoma–still a debate. International Journal of Gynecological Cancer, 20(9), 1531–1534.PubMedGoogle Scholar
  33. Lindor & Greene (2008). SPECIAL ARTICLE. The Concise Handbook of Family Cancer Syndromes. Journal of the National Cancer Institute Monographs, No. 38.Google Scholar
  34. Lowery, M., Kelsen, D., Stadler, Z., Yu, K. H., Janjigian, Y. Y., Ludwig, E., et al. (2011). An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The Oncologist, 16, 1397–1402.PubMedCrossRefGoogle Scholar
  35. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328–2335.PubMedCrossRefGoogle Scholar
  36. Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., et al. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology, 96(1), 222–226.PubMedCrossRefGoogle Scholar
  37. Metcalfe, K. A., Finch, A., Poll, A., Horsman, D., Kim-Sing, C., & Scott, J. (2009). Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. British Journal of Cancer, 100(2), 421–425.PubMedCrossRefGoogle Scholar
  38. Mikaelsdottir, E. K., Valgeirsdottir, S., Eyfjord, J. E., & Rafnar, T. (2004). The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Research, 6, R284–R290.PubMedCrossRefGoogle Scholar
  39. Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., et al. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer, 99(2), 371–374.PubMedCrossRefGoogle Scholar
  40. National Cancer Institute (2009). Breast Cancer Prevention. Description of Evidence. http://www.cancer.gov/cancertopics/pdq/genetics/breast-and ovarian/HealthProfessional#Section_6
  41. National Comprehensive Cancer Network (NCCN) Guidelines, Inc. (2012). Hereditary Breast and/or Ovarian Cancer Syndrome (v.3.2012). http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  42. National Society of Genetic Counselors (NSGC) Code of Ethics (adopted 1/92; revised 1/06) http://www.nsgc.org/Advocacy/NSGCCodeofEthics/tabid/155/Default.aspx
  43. Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62, 145–158.PubMedCrossRefGoogle Scholar
  44. Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.CrossRefGoogle Scholar
  45. Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., et al. (1997). BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genetics, 17, 341–345.PubMedCrossRefGoogle Scholar
  46. Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151–161.PubMedCrossRefGoogle Scholar
  47. Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14(2), 185–187.PubMedCrossRefGoogle Scholar
  48. Saslow, D., Boetes, C., Burke, W., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(57), 75–89.CrossRefGoogle Scholar
  49. Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecological Cancer Predispositions. (2007) Gynecologic Oncology, 107, 159–162.Google Scholar
  50. Stopfer, J. E. (2000). Genetic counseling and clinical cancer genetics services. Seminars in Surgical Oncology, 18, 347–357.PubMedCrossRefGoogle Scholar
  51. Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007). Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNCI, 99(23), 1811–1814.PubMedCrossRefGoogle Scholar
  52. Thompson, D., Easton, D. F., & Breast Cancer Linkage Consortium. (2002). Cancer incidence in BRCA1 mutation carriers. JNCI, 94(18), 1358–1365.PubMedCrossRefGoogle Scholar
  53. Tonin, P. N., Mes-Masson, A. M., Futreal, P. A., Morgan, K., Mahon, M., Foulkes, W. D., et al. (1998). Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics, 63, 1341–1351.PubMedCrossRefGoogle Scholar
  54. Tyrer, J., Duffy, S., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23, 1111–1130.PubMedCrossRefGoogle Scholar
  55. U.S. Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Annals of Internal Medicine, 143(5), 355–361.Google Scholar
  56. van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F., et al. (2005). Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 42(9), 711–719.PubMedCrossRefGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2012

Authors and Affiliations

  • Janice L. Berliner
    • 1
  • Angela Musial Fay
    • 2
  • Shelly A. Cummings
    • 3
  • Brittany Burnett
    • 4
  • Todd Tillmanns
    • 5
  1. 1.Memorial Sloan-Kettering Cancer CenterBasking RidgeUSA
  2. 2.Meridian HealthNeptuneUSA
  3. 3.Myriad Genetic Laboratories, Inc.Salt Lake CityUSA
  4. 4.Sharp HealthcareSan DiegoCA
  5. 5.The West Clinic and The University of TennesseHealth Science CenterMemphisUSA

Personalised recommendations